What is Somatropin?

Somatropin is recombinant human growth hormone, a 191-amino-acid pituitary hormone manufactured as prescription injectable products. [1][2][3]

It has FDA-approved indications such as growth hormone deficiency and selected pediatric growth or wasting contexts, depending on product label. [1][2][3]

That approved-drug evidence does not generalize to anti-aging, bodybuilding, recovery, or performance protocols, which carry different benefit-risk and anti-doping issues. [1][2][3]

What Somatropin is investigated for

Somatropin evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Pediatric growth hormone deficiency and short-stature disorders

Injectable

90% Strong

Pediatric growth-disorder treatment has high-confidence, clinician-managed evidence. [3][1][5][7]

Human evidence

FDA labeling and pediatric endocrine guidelines support somatropin for pediatric growth hormone deficiency and selected short-stature disorders. [3][1][5][7]

Animal / mechanistic evidence

The mechanism is GH receptor and IGF-1 axis replacement in true deficiency or approved pediatric growth-disorder contexts. [3][1][5][7]

Adult growth hormone deficiency

Injectable

82% Strong

Adult GH deficiency should be its own high-confidence indication rather than hidden inside pediatric growth claims. [3][10][12][14]

Human evidence

FDA labeling and adult GH deficiency literature support replacement therapy for diagnosed adult GH deficiency. [3][10][12][14]

Animal / mechanistic evidence

The rationale is physiologic replacement and IGF-1 monitoring, not supraphysiologic enhancement. [3][10][12][14]

HIV-associated wasting

Injectable

80% Strong

HIV-associated wasting is a distinct approved somatropin indication and should be separated from pediatric GHD, adult GHD, and healthy-adult off-label use. [21][18]

Human evidence

Serostim labeling supports somatropin for HIV patients with wasting or cachexia to increase lean body mass, body weight, and physical endurance with concomitant antiretroviral therapy. [21]

Animal / mechanistic evidence

The rationale is anabolic and anticatabolic GH/IGF-1 activity in a defined cachexia indication, not general physique enhancement. [21]

Lean mass, fat loss, aging, and performance use in healthy adults

Injectable

56% Emerging

Lean-mass, fat-loss, and anti-aging claims remain lower confidence and clearly off-label for healthy adults. [12][14][3][20]

Human evidence

Adult GH studies show fat-mass and lean-mass effects in deficiency contexts, but healthy-adult anti-aging and performance use is not an approved indication. [12][14][3][20]

Animal / mechanistic evidence

The mechanism is anabolic and lipolytic GH/IGF-1 signaling, which also explains adverse-effect and anti-doping concerns. [12][14][3][20]

Evidence snapshot

Overall confidence

Strong

90%

Somatropin has strong support for approved growth-hormone replacement and selected endocrine indications. Anti-aging and body-composition use has a different risk-benefit profile. [1][2][3]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

90%

Human evidence

Strong

FDA-approved somatropin products have labeled endocrine indications with dose and safety monitoring. [1][2][3]

34%

Animal / preclinical

Limited

GH receptor and IGF-1 biology directly supports replacement therapy. [1][2][3]

90%

Mechanism support

Strong

Somatropin binds growth hormone receptors and increases hepatic and local IGF-1 signaling. The axis affects growth, body composition, glucose, fluid balance, and tissue turnover. [1][2][3]

Forms & administration

Somatropin is an approved injectable growth-hormone medicine with product- and indication-specific dosing. Prescription replacement therapy is separate from anti-aging or bodybuilding use. [3][18][1]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Norditropin labeling is indication-specific: pediatric GH deficiency uses 0.17-0.24 mg/kg/week divided across 6-7 days per week; adult GH deficiency starts around 0.2 mg/day or 0.004 mg/kg/day with titration. [3][18][1]

Frequency

Pediatric label dosing is divided across 6-7 days per week; adult replacement is typically daily with clinician-directed titration. [3][18][1]

Timing Considerations

Evening timing is often cited for growth-hormone replacement routines, while the prescription label centers consistent scheduled injection and dose adjustment. [3][18][1]

Cycle Length

Somatropin treatment is a medical-supervision-only protocol with IGF-1, glucose, growth, edema, joint symptoms, and indication-specific follow-up. [3][18][1]

What to expect

First weeks

Injectable somatropin replacement may feel like shifts in energy, sleep, body-fluid balance, or adult GH-deficiency symptoms. [1][2][3][18]

Months

Injectable treatment outcomes unfold through pediatric growth velocity or adult body composition, symptoms, IGF-1, and metabolic labs. [1][2][3][18]

After stopping

Hormone-axis effects drift toward baseline after injectable somatropin stops unless the underlying deficiency is treated another way. [1][2][3][18]

Safety profile

Somatropin has prescription-label safety concerns around glucose, fluid retention, joint symptoms, malignancy, intracranial pressure, retinopathy, and pediatric indication limits. [3][1][2]

Common side effects

Fluid retention [3][1][2]
Joint discomfort [3][1][2]
Muscle pain [3][1][2]
Glucose changes [3][1][2]

Cautions

Active malignancy [3][1][2]
Acute critical illness [3][1][2]
Diabetes / retinopathy [3][1][2]
Intracranial pressure [3][1][2]

What we don't know

Anti-aging, bodybuilding, and other non-replacement uses have a different risk-benefit profile from approved somatropin therapy. [3][1][2]

Who Somatropin is not for

Route-specific avoid and medical-review notes:

Active malignancy
Active malignancy warrants medical review or avoidance for Somatropin. [3][1][2]
Acute critical illness per label
Acute critical illness per label use warrants medical review or avoidance for Somatropin. [3][1][2]
Pregnancy or breastfeeding without clinician review
Pregnancy or breastfeeding without clinician review warrants medical review or avoidance for Somatropin. [3][1][2]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Documented interactions

Glucocorticoids
The Norditropin label states somatropin can reduce cortisol concentrations and glucocorticoid replacement doses may require adjustment. [3][1][2]
CYP450-metabolized drugs
The Norditropin label says somatropin may alter clearance of drugs metabolized by CP450 liver enzymes. [3][1][2]
Oral estrogen
The Norditropin label states oral estrogens may reduce IGF-1 response and higher somatropin doses may be required. [3][1][2]
Insulin / hypoglycemic agents
The Norditropin label states somatropin may decrease insulin sensitivity and diabetes medications may require dose adjustment. [3][1][2]

Theoretical interactions

GH secretagogues
Ipamorelin, GHRPs, sermorelin, or IGF products can stack GH/IGF exposure, edema, and glucose effects; this is a GH/insulin-axis caution. [3][1][2]
Anabolic hormones
Testosterone or anabolic agents can compound edema, sleep-apnea, and growth-signal tracking; this is a theoretical pathway caution. [3][1][2]

Regulatory status

United States

In the U.S. as of 2026-06-21, somatropin injection has FDA-approved product labels for specific growth hormone indications. Anti-aging, bodybuilding, and casual wellness use are not approved indications, and compounded products are separate from the labels. [3][18][19][23]

Route	FDA drug approval	503A compounding
Injectable	Approved FDA-approved somatropin injection products exist for labeled growth hormone deficiency and related indications; anti-aging, bodybuilding, or wellness use is outside those labels. [3][18][18]	Not Listed 503A compounding for Somatropin is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved. [3][18][18][19][23][24]

Injectable

FDA drug approval

Approved

FDA-approved somatropin injection products exist for labeled growth hormone deficiency and related indications; anti-aging, bodybuilding, or wellness use is outside those labels. [3][18][18]

503A compounding

Not Listed

503A compounding for Somatropin is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved. [3][18][18][19][23][24]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. A U.S. FDA approval does not automatically establish the same approved indication, route, or product status in those markets. [26][27][28][29]

Sports & competition

WADA S2 prohibits growth hormone; tested athletes should not use somatropin unless a valid TUE and sport-specific anti-doping review apply. [20][18][19][23][24]

How it works

Somatropin binds growth hormone receptors and increases hepatic and local IGF-1 signaling. In plain terms, it replaces or augments a hormone axis that affects linear growth, body composition, glucose handling, water retention, and tissue turnover. [1][2][3]

Injectable prescription use is inseparable from monitoring. The same GH/IGF-1 pathway explains glucose intolerance, edema, joint symptoms, intracranial-pressure symptoms, neoplasm-history review, and pediatric growth-plate status, so wellness or bodybuilding extrapolations are not route-labeled medicine. The route is medical only when paired with diagnosis and follow-up. [1][2][3]

Research gaps & open questions

What the current literature has not yet settled about Somatropin:

A key evidence gap is clearer risk-benefit for off-label aging claims. [1][2][3]

A key evidence gap is long-term safety in non-deficient users. [1][2][3]

A key evidence gap is product-specific monitoring outside endocrine care. [1][2][3]

Common questions

Is somatropin HGH?

Yes. Somatropin is recombinant human growth hormone, an injectable prescription product used for specific labeled growth hormone indications. [18][19][3][1]

Is somatropin FDA-approved?

Yes. Somatropin injection products are FDA-approved in the U.S. for specific labeled growth hormone indications. [18][19][3][1]

Is HGH approved for anti-aging?

No. HGH is not FDA-approved for anti-aging or performance use; those outcomes are separate from approved somatropin indications. [18][19][3][1]

Myths & misconceptions

Myth

HGH is just a recovery peptide.

Reality

It is a systemic hormone with glucose, fluid, cancer-history, and endocrine monitoring issues. [1][2][3]

Myth

FDA approval makes any HGH use legitimate.

Reality

Approval is indication-, product-, and route-specific. [1][2][3]

History & discovery

Somatropin replaced earlier pituitary-derived growth hormone with recombinant human growth hormone products that could be manufactured consistently. Its history is prescription endocrinology, not generic wellness. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3]

Recombinant somatropin became established for specific pediatric and adult growth-hormone indications. That history tied dosing to diagnosis, monitoring, and product labeling. [1][2][3]

Clinical guidelines separated supported growth-hormone uses from weaker or off-label claims. Anti-aging and performance markets grew anyway, making safety and legality central to modern interpretation. [1][2][3]

Published research 21 studies

[1]

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.

Horm Res Paediatr, 2016. review.

[2]

Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence.

Curr Opin Pediatr, 2017 Aug. review.

[3]

NORDITROPIN somatropin injection prescribing information

U.S. Food and Drug Administration. official guidance.

[4]

Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.

Eur J Endocrinol, 2022 Apr 21. review.

[5]

Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.

Horm Res Paediatr, 2019. review.

[6]

Growth hormone therapy and treatment outcomes: current clinical practice of the Gulf Cooperation Council.

Expert Rev Endocrinol Metab, 2014 Jul. review.

[7]

Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society.

J Clin Endocrinol Metab, 2000 Nov. review.

[8]

Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society.

Pituitary, 2025 May 7. review.

[9]

A review of guidelines for use of growth hormone in pediatric and transition patients.

Pituitary, 2012 Sep. review.

[10]

Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway.

Growth Horm IGF Res, 2019 Jun-Aug. review.

[11]

Isolated growth hormone deficiency in children and adolescents.

J Pediatr Endocrinol Metab, 2001 Jul. review.

[12]

Comparison of low-normal and high-normal IGF-1 target levels during growth hormone replacement therapy: A randomized clinical trial in adult growth hormone deficiency.

Eur J Intern Med, 2016 Jun. human clinical.

[13]

Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence.

Arch Dis Child, 2016 Jan. review.

[14]

Growth hormone deficiency in the adult.

Pituitary, 2006. review.

[15]

Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood.

Pituitary, 2007. review.

[16]

Diagnosis and management of congenital hypopituitarism in children.

Arch Pediatr, 2024 Apr. review.

[17]

[Growth hormone treatment update].

Arch Argent Pediatr, 2014 Feb. review.

[18]

Drugs@FDA/openFDA query for Somatropin

U.S. Food and Drug Administration. database query.

[19]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[20]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.

[21]

SEROSTIM somatropin prescribing information

FDA, 2017. regulatory.